Bangladesh signs deal with Indian co to import vaccine
3cr doses of Oxford-AstraZeneca drug to arrive from Jan
Staff Correspondent | Published: 14:22, Nov 05,2020 | Updated: 00:46, Nov 06,2020
The health ministry on Thursday signs a tripartite contract with the Serum Institute of India and Beximco Pharmaceuticals for importing three crore doses of COVID-19 vaccine, developed by Oxford-AstraZeneca. - New Age photo
The health ministry on Thursday signed a tripartite contract with Serum Institute of India Private Limited and local pharmaceutical company Beximco Pharmaceuticals Limited to import three crore doses of a COVID-19 vaccine, developed by Oxford-AstraZeneca, from January.
The three crore doses would be used, on a priority basis, to vaccinate 1.5 crore frontline workers like health workers, police, journalists, and ailing people as well, health minister Zahid Maleque said at the post-agreement signing press briefing at his office.
‘The Oxford-AstraZeneca COVID-19 vaccine will be imported after it gets approval from the World Health Organisation,’ he said, adding that Serum Institute would export 50 lakh doses to Bangladesh per month. Each person will be required to take two doses of the vaccine, he said. Health secretary Md Abdul Mannan, Indian high commissioner Vikram Kumar Doraiswami, Serum Institute’s additional director Sandeep C Mulay, Beximco Pharma managing director Nazmul Hassan Papon, among others, were present at the ceremony.
According to the contract, the government will pay $5 for each of the doses to Serum Institute, including $4 as price and $1 for carrying it maintaining the required temperature.
Serum Institute will pay its local agent Beximco Pharma for carrying the vaccines from the former’s warehouse to the Bangladesh government’s warehouse, according to the tripartite deal. Serum Institute, one of the world’s largest manufacturers of vaccines, is producing one billion doses of the Oxford-AstraZeneca vaccine, an adenovirus vector-based vaccine. The COVID-19 vaccine is currently undergoing large-scale phase-III trials in Brazil, US, UK and India and is expected to receive approval by the end of 2020.
More:
www.newagebd.net
3cr doses of Oxford-AstraZeneca drug to arrive from Jan
Staff Correspondent | Published: 14:22, Nov 05,2020 | Updated: 00:46, Nov 06,2020
The health ministry on Thursday signs a tripartite contract with the Serum Institute of India and Beximco Pharmaceuticals for importing three crore doses of COVID-19 vaccine, developed by Oxford-AstraZeneca. - New Age photo
The health ministry on Thursday signed a tripartite contract with Serum Institute of India Private Limited and local pharmaceutical company Beximco Pharmaceuticals Limited to import three crore doses of a COVID-19 vaccine, developed by Oxford-AstraZeneca, from January.
The three crore doses would be used, on a priority basis, to vaccinate 1.5 crore frontline workers like health workers, police, journalists, and ailing people as well, health minister Zahid Maleque said at the post-agreement signing press briefing at his office.
‘The Oxford-AstraZeneca COVID-19 vaccine will be imported after it gets approval from the World Health Organisation,’ he said, adding that Serum Institute would export 50 lakh doses to Bangladesh per month. Each person will be required to take two doses of the vaccine, he said. Health secretary Md Abdul Mannan, Indian high commissioner Vikram Kumar Doraiswami, Serum Institute’s additional director Sandeep C Mulay, Beximco Pharma managing director Nazmul Hassan Papon, among others, were present at the ceremony.
According to the contract, the government will pay $5 for each of the doses to Serum Institute, including $4 as price and $1 for carrying it maintaining the required temperature.
Serum Institute will pay its local agent Beximco Pharma for carrying the vaccines from the former’s warehouse to the Bangladesh government’s warehouse, according to the tripartite deal. Serum Institute, one of the world’s largest manufacturers of vaccines, is producing one billion doses of the Oxford-AstraZeneca vaccine, an adenovirus vector-based vaccine. The COVID-19 vaccine is currently undergoing large-scale phase-III trials in Brazil, US, UK and India and is expected to receive approval by the end of 2020.
More:
Bangladesh signs deal with Indian co to import vaccine
The health ministry on Thursday signed a tripartite contract with Serum Institute of India Private Limited and local pharmaceutical company Beximco Pharmaceuticals Limited to import...
www.newagebd.net
Last edited:
